Assessment of the prognostic value of RPL4P4 expression in glioma patients subgrouped by WHO grade, 1p/19q codeletion, IDH mutation status, recurrence, and age showed that high expression of RPL4P4 was associated with poor prognosis in all of these groups (Figures 3(a)–3(h)). Here, IDH1 is linked to central nervous system cancer.